Safety profile of darolutamide versus placebo: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis

Published:2023-12-14 Issue: Volume: Page:
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Turco Fabio^ORCID,Gillessen Silke,Treglia Giorgio^ORCID,Fizazi Karim,Smith Matthew R.,Tombal Bertrand^ORCID,Cathomas Richard,Buttigliero Consuelo,Di Maio Massimo^ORCID,Tucci Marcello^ORCID,Vogl Ursula M.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-023-00775-y.pdf

Reference40 articles.

1. Baumgart SJ, Nevedomskaya E, Lesche R, Newman R, Mumberg D, Haendler B. Darolutamide antagonizes androgen signaling by blocking enhancer and super-enhancer activation. Mol Oncol. 2020;14:2022–39.

2. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014;15:975–85.

3. Massard C, Penttinen HM, Vjaters E, Bono P, Lietuvietis V, Tammela TL, et al. Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol. 2016;69:834–40.

4. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383:1040–9.

5. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132–42.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current status and perspectives on the use of androgen receptor pathway inhibitors in the salvage radiotherapy setting;Prostate Cancer and Prostatic Diseases;2024-08-13